keyboard_arrow_up

Global Parkinson's Disease Market 2014-2018

Global Parkinson's Disease Market 2014-2018 is a new market research publication announced by Reportstack. Parkinson’s disease is a progressive neurodegenerative disorder characterized by damage of dopaminergic neurons located in various parts of brain including the substantia nigra. This lowers the concentration of dopamine in the striatum. A decrease in dopamine levels by 80 percent leads to the development of symptoms associated with Parkinson’s disease such as tremor, bradykinesia, and muscular rigidity. It is usually diagnosed in the population aged 60 and over; however, earlier incidences have been reported. Based on the severity, it can be categorized into early stage, mid stage and late (or advanced) stage. Currently, the approved therapies provide only symptomatic relief. Levodopa is the standard drug for the treatment of Parkinson’s disease; however, it is associated with the incidence of dyskinesias. Alternative surgical procedures such as bilateral globus pallidus interna stimulation and bilateral subthalamic nucleus stimulation can be used in Parkinson’s disease patients under certain circumstances.

The analysts forecast that the Global Parkinson’s Disease market will grow at a CAGR of 3.32 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Parkinson’s Disease market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to provide symptomatic relief in Parkinson’s disease. 

The report also presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the Global Parkinson’s Disease market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. The report Global Parkinson’s Disease Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Parkinson’s Disease market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas 
• EMEA 
• APAC
Key Vendors
• Boehringer Ingelheim GmbH
• GlaxoSmithKline plc
• Novartis AG 
• Teva Pharmaceutical Industries Ltd.
Other Prominent Vendors
• Abbvie Inc.
• Akorn Inc.
• Astellas Pharma Inc.
• Desitin Arzneimittel GmbH
• Endo International plc
• F. Hoffmann-La Roche Ltd.
• H. Lundbeck A/S
• Kyowa Hakko Kirin
• Merck & Co. Inc.
• Orion Corp.
• STADA Arzneimittel AG
• UCB Inc.
• US WorldMeds LLC
• Valeant Pharmaceuticals International Inc.
Key Market Driver
• Increase in Patient Population
• For a full, detailed list, view our report.
Key Market Challenge
• Generic Erosion
• For a full, detailed list, view our report.
Key Market Trend
• Reformulation of Marketed Drugs
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?


Companies Mentioned

Boehringer Ingelheim GmbH,GlaxoSmithKline plc,Novartis AG ,Teva Pharmaceutical Industries Ltd.,Abbvie Inc. ,Akorn Inc.,Astellas Pharma Inc.,Desitin Arzneimittel GmbH,Endo International plc,F. Hoffmann-La Roche Ltd.,H. Lundbeck A/S,Kyowa Hakko Kirin,Merck & Co. Inc.,Orion Corp.,STADA Arzneimittel AG,UCB Inc.,US WorldMeds LLC,Valeant Pharmaceuticals International Inc.

To view the table of contents and know more details please visit Global Parkinson's Disease Market 2014-2018.